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Abstract
Background: Metastasis is a multi-step process that is responsible for the majority of deaths in cancer patients. Current 
treatments are not effective in targeting metastasis. The molecular chaperone hsp90α is secreted from invasive cancer 
cells and activates MMP-2 to enhance invasiveness, required for the first step in metastasis.
Methods: We analyzed the morphology and motility of invasive cancer cells that were treated with exogenous 
exosomes in the presence or absence of hsp90α. We performed mass spectrometry and immunoprecipitation to 
identify plasminogen as a potential client protein of extracellular hsp90α. Plasmin activation assays and migration 
assays were performed to test if plasminogen is activated by extracellular hsp90α and has a role in migration.
Results: We found that hsp90α is secreted in exosomes in invasive cancer cells and it contributes to their invasive 
nature. We identified a novel interaction between hsp90α and tissue plasminogen activator that together with annexin 
II, also found in exosomes, activates plasmin. Extracellular hsp90α promotes plasmin activation as well as increases 
plasmin dependent cell motility.
Conclusions: Our data indicate that hsp90α is released by invasive cancer cells via exosomes and implicates hsp90α in 
activating plasmin, a second protease that acts in cancer cell invasion.
Background
Approximately 90% of cancer deaths are not from the pri-
mary tumor but due to metastasis to distant sites [1].
Current treatments do not target metastatic disease.
Towards developing anti-metastasis drugs, a functional
proteomic screen was performed to identify surface pro-
teins required for tumor cell invasion, the first step in
metastasis [2]. One of the proteins identified was the
molecular chaperone heat shock protein 90α (hsp90α)
[2]. Intracellular hsp90α aids in the folding, assembly-dis-
assembly and activation of a variety of client proteins
including kinases, steroid hormone receptors and tran-
scription factors [3]. We discovered that extracellular
hsp90α acts in tumor cell invasion through its activation
of the pro-invasive protein matrix metalloproteinase-2
(MMP-2). Since the publication of this study, additional
reports in the literature have demonstrated the impor-
tance of extracellular hsp90α in both physiological and
pathological states. Extracellular hsp90α is required for
both dermal fibroblast [4] and neuronal motility [5] as
well as for melanoma migration [6], invasion and metas-
tasis [7].
The secretion method of extracellular hsp90α from
invasive cancer cells has not been fully elucidated.
Hsp90α has been found in exosomes in immune and
other physiologically normal cell types [8-11] and sug-
gested to be in exosomes in diabetic cells [12]. Exosomes
are small vesicles, approximately 30-100 nM in diameter,
that are part of the endocytic pathway. They are secreted
as intact vesicles that form within multivesicular bodies
(MVB) and are released from cells when the membrane of
the MVB fuses with the plasma membrane. Exosomes
function in the immune system and in acellular commu-
nication [13]. Recent reports indicate that exosomes con-
tribute to the aggressive nature of gliomas by transferring
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the mutated EGFRvIII receptor between cells [14]. The
presence of hsp90α in exosomes of other cells types and
the observation that exosomes contribute to glioma
aggressiveness suggested to us that hsp90α in exosomes
might contribute to cancer invasiveness.
In this study, we demonstrate that hsp90α is secreted
from invasive cancer cells via exosomes and increases
cancer cell migration. We show that extracellular hsp90α
is necessary for the activation of a second extracellular
protease, plasmin, and that fibrosarcoma cell movement
is dependent on this activation.
Methods
Cell culture
A172, HT-1080, and MDA-MB231 cells were obtained
from ATCC and maintained in DMEM supplemented
with 10% FBS, 1% NEAA, and 1% P/S. SUM159 cells were
a kind gift from Charlotte Kuperwasser and were main-
tained in Hams F12 media supplemented with 5% FBS, 5
μg/mL insulin, 10 ng/mL EGF and 1% P/S. All cells were
grown in a 37°C incubator with 7.5% CO2.
Quantitative Real time PCR
Total RNA was extracted from MDA-MB231 breast can-
cer cell lines with TRIzol (Invitrogen, California) and 2 μg
of RNA was reverse transcribed into cDNA with Super-
script III (Invitrogen) following the instructions supplied
by the supplier. Real time PCR was performed at the Tufts
Univesity Center for Neuroscience Research using the
Stratagene real time cycler. Primer sequences were as fol-
lows: HSP90AA1-1 forward 5'-GGCAGAGGCTGA-
TAAG-AACG-3' and reverse 5'CCCAGACCAAGT
TTGATCATCC-3'; HSP90AA1-2 forward 5'-CATCT-
GATGGTGTCTGGATCC-3' and reverse 5'-AATGGCT-
GCAGATCCTTGTAG-3'. Samples were analyzed using
the 2-ΔΔCT method (29) with GAPDH as the reference.
Brefeldin A Treatment
MDA-MB231 cells were treated with 10 μg/mL Brefeldin
A (BFA), (Sigma, Missouri) or vehicle control for 16
hours. Conditioned media was collected, concentrated
and subjected to SDS-PAGE followed by a Western blot
probed with MMP-2 antibody (EMD Biosciences, New
Jersey), anti-hsp90α or β-actin antibody (Sigma, Mis-
souri). β-actin protein should be absent in conditioned
media samples isolated from intact, alive cells.
RNAi Treatment
MDA-MB231 cells were transfected with either control
siRNA (non-targeting) or 100 nM siRNA directed against
the HSP90AA1-2 (sense 5'-GTTAACTGGTACCAA-
GAAA-dTdT-3') isoform using Oligofectamine (Invitro-
gen). RNA was extracted as indicated above and the
results are graphed as percentage knockdown setting the
control at 100%.
Exosome isolation
Exosomes were isolated from A172, HT-1080, MDA-
MB231, and SUM159 cells as previously described [8].
Briefly, 5 × 106 cells were plated in 10% DMEM and
allowed to settle overnight. Cells were then washed with
HBSS and re-fed with serum free media or serum free
media containing 15 nM dimethyl amiloride (Sigma).
Media was collected 48 hours after the addition of serum
free DMEM and spun at 300 × g to collect any cellular
debris. This media was then filtered with a 0.2 μM filter
and spun for 1 hour at 110,000 × g. The pellet was washed
with PBS and spun for 1 hour at 110,000 × g. One μg of
protein was subjected to Western Blot probed for hsp90α
(Assay Designs, Michigan). Samples were also probed
with an anti-Annexin II antibody (BD Biosciences, Cali-
fornia) and Flotillin (Cell Signaling Technology, Massa-
chusetts) as positive controls and vATPase subunit B
(Molecular Probes, California) as a negative control.
Immunostaining
1 × 104 MDA-MB231 cells were plated into an 8-well
chamber slide and treated with exosomes isolated from
MDA-MB231 cells or 0.5 μg recombinant hsp90α (Assay
Designs) for 16 hours. Cells were fixed in PBS/4% para-
formaldehyde/4% sucrose, permeabilized in 0.1% Tri-
tonX-100/PBS, blocked in 1%BSA/PBS and stained with
Alexa546-labeled phalloidin (Invitrogen, CA) for 30 min-
utes to visualize F-actin.
Cell shape analysis
The cell shape and area of MDA-MB231 cells were mea-
sured and calculated with OpenLab software (Improvi-
sion). Cell shape was defined using the equation (4 × cell
area)/cell perimeter2, where greater than 1 indicates a
perfect circle and values less than 1 indicate a more irreg-
ular shape.
Wound healing assay
1 × 105 SUM159 breast cancer cells or A172 glioma cells
were plated in an 8 well chamber slide. Cells were
wounded by scratching a sterile yellow pipette tip length-
wise along the chamber. The cells were washed twice with
1× PBS and serum free media was placed in each well
with either the vehicle control PBS, 0.5 μg recombinant
hsp90α protein, 1 μg exosomes isolated from SUM159
cells, or 1 μg exosomes isolated from SUM159 cells plus
40 μg/mL anti-hsp90 antibody (SPS-771, Assay Designs).
Pictures were taken immediately after cell wounding (0
hours) and 16 hours after cell wounding. Wound width
was calculated using OpenLab software and is repre-
sented as μm between the cells at 16 hours for each treat-
ment.McCready et al. BMC Cancer 2010, 10:294
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Immunoprecipitation/Mass spectrometry
4 × 106 MDA-MB231 breast cancer cells were plated in a
150 mm tissue culture dish and allowed to settle for 24
hours. Cells were then refed with serum free media and
incubated for 48 hours at 37°C. Conditioned media was
concentrated by centrifugation (Millipore, MA) and a
protein assay was performed (BioRad, CA). 1 mg of pro-
tein was pre-cleared with protein A beads after which 1
ug of hsp90α antibody (Assay Designs) was added to the
samples. Samples were washed with RIPA B buffer (50
mM Tris, 150 mM NaCl, 0.5% NP40, 0.25% DOC) boiled,
subjected to SDS PAGE, stained with Coomassie Blue
and removed from the gel for mass spectrometry analysis.
The excised gel bands were analyzed by mass spectrome-
try as previously described [15]. MS results were verified
using antibodies for hsp90α and tPA (Abcam, MA).
Plasminogen activation assay
Plasminogen activation assays were performed as previ-
ously described [16]. Briefly, HT-1080 fibrosarcoma cells
were plated in 10% DMEM and refed with serum free
media 24 hours after plating. DMSO, 0.5 μM [Glu] plas-
minogen (American Diagnostica Inc, CT), or 40 μg/mL
DMAG-N-oxide (a gift from Len Neckers) were added for
five hours at 37°C. DMAG-N-oxide was used in this
experiment because the large amount of antibody
required for this experiment precluded its use. It has been
previously characterized as an inhibitor of extracellular
hsp90α [17]. Conditioned media was concentrated (Milli-
pore) and a protein assay was performed (Bio-Rad). 25 μg
of each sample was loaded into a 0.1% gelatin zymogram.
The zymogram was washed twice for two hours each in
wash buffer (50 mM Tris-HCl, 150 mM NaCl, 2.5% (v/v)
Triton X-100, pH 7.4), three times for 5 minutes each in
water and then incubated in wash buffer for 12 hours at
37°C. The zymogram was stained with 0.5% coomassie,
destained, and densitometry was performed to determine
the plasminogen activation levels of each condition.
Migration assay
HT-1080 fibrosarcoma cells were plated in 10% DMEM.
48 hours after plating the cells were labeled with
CMTMR (Invitrogen) and 1 × 105  labeled cells were
plated into a 24-well Fluoroblok plate (BD Biosciences,
CA). Cells were treated with either 40 μg/mL rabbit IgG,
40 μg/mL anti-hsp90α (SPS-771, Assay Designs), or 0.5
μg plasmin (Molecular Innovations, MI). Cells were
allowed to migrate for 24 hours after which the number
of cells that migrated to the bottom chamber were photo-
graphed and counted.
Results
Hsp90α is secreted via exosomes in invasive cancer cells
While the importance of extracellular hsp90α for tumor
cell migration, invasion and metastasis has been recog-
nized, the mechanism that invasive tumor cells use to
secrete hsp90α is still unclear. In response to our work
(2), it was hypothesized that alternative splicing of
hsp90α created multiple isoforms and that perhaps there
was a mainly intracellular hsp90α isoform and a mainly
extracellular isoform of hsp90α (18). This was of interest
because one could then target drugs to the extracellular
isoform without interfering with the important intracel-
lular functions of hsp90α. We verified that the two
hypothesized Hsp90α isoforms existed in MDA-231 cells
and determined the relative amounts using Real Time
PCR (Figure 1a). We found that the primary isoform
present in MDA-231 cells was the classical ten-exon iso-
form (AA1-1). The other isoform, AA1-2, with two addi-
tional exons, was present in only very small quantities.
Even though there was only a small amount of the second
isoform present, we hypothesized that this isoform could
be targeted outside of the cell since the amount of
Hsp90α inside of the cell is much greater than the amount
outside of the cell. In order to test if Hsp90α was indeed
being exported via a signal sequence in the two extra
exons, we treated MDA-231 cells with Brefeldin A, a
compound that inhibits the export of proteins through
the canonical pathway. We collected the conditioned
media from the cells, subjected it to SDS-PAGE and blot-
ted for Hsp90α (Figure 1b). Hsp90α was detected outside
Figure 1 Hsp90α is not secreted either through the classic secre-
tory pathway or in an isoform specific fashion. (a) We identified 
two isoforms of hsp90α in breast cancer cell lines using quantitative 
real time PCR. Cells were transfected with either control siRNA (non-
targeting) or 100 nM siRNA directed against the HSP90AA1-2 isoform. 
Data from one of the three cell lines tested are represented (A172 and 
HT1080 not shown). (b) MDA-MB231 cells were treated with BFA or ve-
hicle control for 16 hours and conditioned media was collected, con-
centrated and subjected to SDS-PAGE followed by a Western blot 
probed with anti-hsp90α, MMP-2 or β-actin antibody. (c) Conditioned 
media from cells treated with siRNA directed against the HSP90AA1-2 
isoform was collected, concentrated and subjected to SDS-PAGE fol-
lowed by a Western blot probed with an anti-hsp90α antibody.
a)
Ctl BFA
hsp90˞
˟ actin
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siCTL siAA1-2
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of the cell after BFA treatment in both cell lines indicating
that it is not exported through the canonical signal
sequence pathway. In fact, the extracellular hsp90α pro-
tein levels were markedly increased by Brefeldin A, prob-
ably in response to cellular stress caused by this inhibitor.
As a positive control we probed for MMP-2, a protein
known to be exported via a signal sequence, and we
found that its secretion was markedly inhibited by BFA
(Figure 1b).
Even though Hsp90α is not exported via a signal
sequence, it may still be exported in an isoform specific
manner. In order to test this we used siRNA to knock
down the AA1-2 isoform. We obtained approximately
80% knock down of this isoform in the cells (Figure 1a)
but did not see any reduction in the amount of Hsp90α
outside of the cell (Figure 1c). These results indicate that
hsp90α is not secreted by the classical secretory pathway
or in an isoform specific manner. This led us to explore
other non-classical secretory pathways such as exosomes.
We isolated exosomes from MDA-MB231 cells and
showed by immunoblot that they contain hsp90α (Figure
2a). T o test the generality of this, we isolated exosomes
from three other invasive tumor cell lines from different
lineages, A172 glioblastoma cells, HT-1080 fibrosarcoma
cells, and SUM159 breast cancer cells. The exosomes iso-
lated from these cells also contain hsp90α (Figure 2a).
Purity of our exosome preparations was verified by the
presence of annexin II and flotillin, two markers for exo-
somes, as well as by the absence of the large B subunit of
the v-ATPase (Figure 2b), which is found in lysosomes
and plasma membrane but not in exosomes [18]. When
cells were treated with dimethyl amiloride (DMA), which
blocks the exosome pathway[19], isolated exosome prep-
arations from all cell lines tested showed marked reduc-
tion in hsp90α as well as exosome markers (Figure 2a).
Both hsp90α and annexin II were degraded in a protease
protection assay suggesting that they are easily accessible
to extracellular proteins (data not shown). Therefore,
h s p 9 0 α  i n  e x o s o m e s  i s  a c c e s s i b l e  t o  a c t i v a t e  s e c r e t e d
extracellular proteins such as MMP-2 [2].
Exosomes induce a change in morphology of breast cancer 
cells
Recent reports indicate that cancer cells secrete exo-
somes containing annexins and major histocompatibility
complex proteins, which are normally associated with
exosomes but also contain proteins involved in cell adhe-
sion and motility such as integrins and fibronectin [20-
22]. These reports, along with our previously published
data regarding the role of extracellular hsp90α and tumor
cell motility, suggest that exosomes containing hsp90α
released by invasive cancer cells could increase tumor cell
motility. To test this hypothesis we isolated exosomes
from the breast cancer cell line MDA-MB231, added
them to the media of MDA-MB231 cells plated the previ-
ous day and stained the cells with phalloidin to analyze
the morphology of the cells in the presence of exosomes
(Figure 3a). Cells exposed to the control vehicle, PBS, dis-
play normal morphology, whereas cells exposed to exo-
somes for 16 hours show a more polarized shape
associated with a motile phenotype. We also exposed
MDA-MB231 cells to recombinant hsp90α protein to
determine if the effect we see with the exogenous exo-
somes is due in part to the presence of hsp90α in the exo-
somes. Hsp90α treated cells are more polarized than
control-treated cells but less polarized than the cells
treated with exosomes. To quantitate these changes, we
measured both the cell shape and cell area using the
OpenLab software program (Figure 3b). A motile cell can
have a more linear cell shape as well as a large cellular
area. We measured the perimeter of cells treated with
either PBS, recombinant hsp90α protein or exosomes.
The data are represented in a Chang plot that depicts the
shape of cells in which a perfect circle is greater than 1
and a perfect line is 0. Cells treated with PBS have the
most circular shape (average = 0.79 ± 0.02), cells treated
with exosomes have the least circular shape (average =
0.49 ± 0.02) and cells treated with recombinant hsp90α
show intermediate values between those seen for control
and exosome treated cells (average = 0.61 ± 0.03). Cells
treated with either the recombinant hsp90α or exosomes
are statistically significantly different in shape when com-
pared to the control treated cells (p < 0.001). Exosome
treatment also significantly increases the cell area when
compared to cells treated with PBS or recombinant
Figure 2 Hsp90α is present in the exosomes of four cancer cell 
lines. Western blot analysis of exosomes isolated from invasive cancer 
cell lines treated with vehicle (-) or DMA (+), which blocks the exosome 
pathway. Proteins were resolved by electrophoresis on 10% SDS-PAGE 
and transferred to a nitrocellulose membrane. Western blot was per-
formed using hsp90α, annexin II, flotillin, and vATPase antibodies. Rep-
resentative images taken from three independent experiments are 
shown.
hsp90
annexin II
a)
- +     - +     - +     - +   
flotillin
DMA
MDA SUM159 A172 HT-1080
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hsp90α (Figure 3c). Cell area increased from an average of
1137 ± 121 μm2 to an average of 1398 ± 138 μm2 with the
addition of recombinant hsp90α (p < 0.02) and further
increased to an average of 1914 ± 167 μm2 with the addi-
tion of exosomes (p < 0.001). Taken together these results
indicate that exogenous exosomes cause changes in both
cell shape and cell area, consistent with motile behavior.
We performed this experiment with A172 glioma cells
(data not shown), however since they display a polarized
morphology under normal growing conditions, the addi-
tion of exosomes did not affect their morphology.
Exosomes increase cancer cell motility
To determine if the changes in cell morphology translate
to an increase in cell motility we performed wound heal-
ing assays. Since MDA-MB231 cells are not well suited to
the wound healing assay we used two highly motile and
invasive cell lines originating from different tumors:
SUM159 breast cancer cells (Figure 4a) and A172 glioma
cells (Figure 4b). We imaged the wound immediately after
wounding the cells (0 hours) and added either recombi-
nant hsp90α, exosomes, or exosomes plus a function
inhibiting hsp90α antibody [4]. We captured a second set
of images 16 hours later. SUM159 control cells moved
significantly less than cells treated with either 0.5 μg
recombinant hsp90α (p < 0.05) or 1 μg exosomes (p <
0.01). The effect of exosomes on SUM159 cells was
reduced by the hsp90α function inhibiting antibody sug-
gesting that hsp90α is required for an exosome-depen-
dent increase in cell movement. Control cells moved
significantly less than cells treated with either recombi-
Figure 3  Exosomes alter the morphology of invasive breast cancer cells. Immunofluorescence and cell morphological analysis of MDA-MB231 
cells. (a) Cells were treated with PBS (top panel), exosomes isolated from MDA-MB231 cells (middle panel) or recombinant hsp90α protein (bottom 
panel) and stained with phalloidin to visualize F actin. Images taken at 10× magnification from three independent experiments. Scale bar = 100 μM. 
Inset: Representative images at 20× magnification. (b) Chang plot showing cell shape measurements. Cell shape is defined using the equation (4 × 
cell area)/cell perimeter2, where greater than 1 indicates a perfect circle and smaller values indicate a more irregular shape. Cell shape was calculated 
using OpenLab software. n = 130. (c) Cell area analysis of MDA-MB231 cells treated with exogenous exosomes or recombinant hsp90α. Cell area was 
calculated using OpenLab software. n = 130.
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nant hsp90α (p < 0.05) or exosomes (p < 0.01). A172 cells
acted similarly to SUM159 cells in the wound healing
assay. Data from the wound healing assay is represented
graphically in Figure 4c.
Extracellular hsp90α immunoprecipitates with tissue 
plasminogen activator
Our findings established that the addition of exogenous
exosomes changed both the morphology and motility of
cancer cells. We had previously implicated hsp90α in the
activation of MMP-2, but it is possible that hsp90α
secreted via exosomes could activate other extracellular
proteins. We hypothesized that extracellular hsp90α was
interacting with other extracellular proteins to increase
cancer cell motility. To identify proteins that associate
with hsp90α we performed immunoprecipitation with
conditioned media from MDA-MB231 cells followed by
mass spectrometry (Figure 5a). We discovered ten pro-
teins bound to extracellular hsp90α. The identified pro-
teins are in their precursor form suggesting that they
might be potential clients for this chaperone. We focused
on one that could be linked to both exosomes and cell
motility: tissue plasminogen activator protein (tPA).
Annexin II, a protein secreted via exosomes, binds to
both tPA and plasminogen and has been shown to associ-
ate with hsp90α [23]. This binding initiates conversion of
plasminogen to the protease plasmin [24]. We verified the
mass spectrometry result with co-immunoprecipitation
of Hsp90α and tPA in conditioned media from HT-1080
fibrosarcoma cells (Figure 5b), the cell line for which we
originally discovered the interaction of extracellular
hsp90α and MMP-2, and MDA-MB231 cells (data not
shown). tPA and hsp90α weakly interact in both MDA-
MB231 and HT-1080 cells perhaps because client and
chaperone proteins interact transiently [25]. This raises
the possibility that tPA is a novel client protein for extra-
cellular hsp90α.
Figure 4  Exosomes increase hsp90α dependent glioma and breast cancer cell movement. (a) SUM159 breast cancer cells were wounded and 
images captured immediately and 16 hours after wounding. Cells were treated with either PBS, recombinant hsp90α protein, exosomes isolated from 
SUM159 cells or exosomes isolated from SUM159 cells plus anti-hsp90α antibody. Representative images from three independent experiments are 
shown for each time point and condition. Scale bar = 150 μM (b) A172 glioma cells were wounded and images captured immediately or 16 hours 
after wounding. Cells were treated with either PBS, recombinant hsp90α protein, exosomes isolated from A172 cells or exosomes isolated from A172 
cells plus anti-hsp90α antibody. Representative images from three independent experiments are shown for each time point and condition. Scale bar 
= 150 μM (c) Graphical representation of the wound healing assay with SUM159 and A172 cancer cell lines. The addition of both recombinant hsp90α 
protein and anti-hsp90α antibody results in a significant decrease in wound closure at 16 hours (p < 0.05, p < 0.01 respectively, two tailed t test).
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Hsp90α aids in the conversion of plasminogen to plasmin
Previous data from our lab indicated that extracellular
hsp90α increases cancer cell invasion by assisting in the
activation of MMP-2 [2]. To test if extracellular hsp90α
can promote the activation of other extracellular proteins
involved in cancer cell motility we assessed whether the
activation of plasmin through its association with tPA
requires extracellular hsp90α. We performed plasmin
activation assays with HT-1080 fibrosarcoma cells in the
p r e s e n c e  o r  a b s e n c e  o f  a n  i n h i b i t o r  o f  e x t r a c e l l u l a r
hsp90α (Figure 6a). We used DMAG-N-oxide, an imper-
meable form of the hsp90α inhibitor geldanamycin [17]
to determine if extracellular hsp90α activates plasmin.
The addition of DMAG-N-oxide resulted in a 32%
decrease in activated plasmin when compared to cells
that were treated with vehicle alone (Figure 6b, p < 0.02).
These findings indicate that extracellular hsp90α is
involved in the conversion of plasminogen to plasmin.
Inhibition of extracellular hsp90α decreases tumor cell 
migration
While extracellular hsp90α can activate plasmin, it was
not known if this activation contributes to increased
tumor cell motility. We performed transwell migration
assays using a function-inhibiting antibody against
hsp90α (Figure 7). This antibody will only inhibit the
extracellular hsp90α because antibodies are membrane
impermeant. HT-1080 fibrosarcoma cells treated with the
hsp90α antibody migrated 37% less than control treated
cells (p < 0.01). Interestingly, the addition of plasmin
alone did not increase cell motility. Perhaps the cells are
Figure 5 Extracellular hsp90α co-immunoprecipitates with tissue plasminogen activator. (a) MS/MS spectrum of the peptide 
(248VYTAQNPSAQALGLGK263) that was used to identify tPA as a HSP90α interacting protein. (b) Immunoprecipitation of hsp90α from the conditioned 
media of HT-1080 fibrosarcoma cells. Hsp90α was immunoprecipitated from the media of HT-1080 cells and resolved on 10% SDS-PAGE. Western blot 
analysis was performed using anti-hsp90α or anti-tPA antibodies. The input lane contains approximately 1/100th of the total media collected. "IP Ab" 
indicates the antibody used during immunoprecipitation (hsp90α, tPA or no antibody as the negative control). "IB Ab" indicates which antibody was 
used the probe the immunoblot. Representative images from three independent experiments are shown.
a)
input  Hsp tPA    No
b) IP Ab
tPA
Hsp90
IB Ab
Hsp90McCready et al. BMC Cancer 2010, 10:294
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already saturated with active plasmin such that additional
plasmin would not affect migration. Normal migration
was recovered when we added activated plasmin to the
cells treated with hsp90α antibody. Together, these find-
ings indicate that hsp90α can activate plasmin and this
activity stimulates cell motility.
Discussion
In this study we present evidence that extracellular
hsp90α, secreted via exosomes, activates a novel client
protein and increases tumor cell motility. Previously pub-
lished work from our lab and others indicate that extra-
cellular hsp90α contributes to the activation of both
MMP-2 [2] and HER-2 [26], two proteins involved in can-
cer metastasis. We now present data indicating that
extracellular hsp90α is necessary for the activation of a
second protease, plasmin, also involved in tumor metas-
tasis [27]. Inhibiting extracellular hsp90α in vivo inhibits
both wound healing [4] and tumor invasion [17]. Our
current findings suggest however that other exosomal
proteins may also contribute to these processes. Hsp90α
protein alone does not elicit as complete an effect on cell
morphology or movement as the addition of exosomes
(Figures 3 and 4). Hsp90α binds to tPA and inhibiting
hsp90α decreased plasmin activation and cell migration.
Therefore, we speculate that hsp90α is part of an extracel-
lular complex including annexin II, tPA and plasminogen
that functions to increase cell movement. Annexin II is
found in exosomes and has an established role in aggres-
sive tumors and binds both tPA and plasminogen thereby
enhancing the conversion of plasminogen to active plas-
min [24]. Extracellular hsp90α increases annexin II at the
cell surface in rat aortic cells, leading to an increase in
plasmin production in these cells [23]. Also, cell surface
annexin II expression levels are increased in metastatic
tumors and it interacts with multiple extracellular pro-
Figure 6  Extracellular hsp90α assists in the conversion of plasminogen to plasmin. (a) HT-1080 fibrosarcoma cells were treated with either DM-
SO, plasminogen or plasinogen plus DMAG-N-oxide, a membrane impermeant inhibitor of hsp90α. Samples were added to a gelatin zymogram. A 
representative image taken from three independent experiments is shown. (b) Graphical representation of the plasminogen activation assay. Densi-
tometry results are expressed as the percent decrease in plasmin activation (control set to 100%) and are from three independent experiments. Inhi-
bition of extracellular hsp90α with DMAG-N-oxide results in a 32% decrease in plasmin activation (p < 0.02, two tailed t test).
*
* p < 0.02
Control       Plasminogen    Plasminogen
+ DMAG-N-Oxide a)
b)McCready et al. BMC Cancer 2010, 10:294
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teases that have been implicated in tumor progression
[28]. Although plasmin is known for its role in cellular
invasion it has not been well studied in migration, one
component of the multi-step process of tumor invasion.
Plasmin may be contributing to cell migration by contrib-
uting to the local remodelling of the extracellular matrix
exposing cryptic cell attachment sites necessary for cellu-
lar migration, similar to that seen in smooth muscle cells
during wound healing [29]. It is also possible that plasmin
contributes to cell migration by interacting with currently
unknown targets.
We suggest that exosome contents are released outside
the tumor cell in close proximity to each other and other
inactive extracellular pro-invasive proteins such as plas-
minogen. Once released from the exosomes, extracellular
hsp90α assists in the activation of pro-MMP2 as well as
plasminogen. Beyond MMP-2 and plasmin it is possible
that hsp90α could activate other extracellular proteins as
most of the proteins identified by mass spectrometry in
this study were found in their inactive pro-forms. It is
therefore interesting to speculate that extracellular
hsp90α could activate a cassette of proteins that function
collectively in cancer cell migration. These proteins
would act in concert to enhance breakdown and remodel-
ing of the extracellular matrix and permit the tumor cell
to invade its microenvironment. Thus, inhibition of
extracellular hsp90α could inhibit a growing number of
proteins that are responsible for increased tumor cell
movement making extracellular hsp90α an attractive tar-
get for drug therapy to limit tumor invasion.
Conclusions
In summary, we have identified that exosomes increase
cell motility. One mechanism for this increased motility is
the activation of plasmin by extracellular hsp90α. The
discovery of a second protease activated by extracellular
hsp90α suggests the possibility that the one role of extra-
cellular hsp90α in cancer cells is the activation of precur-
sor proteins that contribute to cellular migration and
invasion.
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